Document Detail


Otelixizumab: a novel agent for the prevention of type 1 diabetes mellitus.
MedLine Citation:
PMID:  21913874     Owner:  NLM     Status:  Publisher    
Abstract/OtherAbstract:
Introduction: Type 1 diabetes mellitus is a chronic, progressive autoimmune disorder linked to numerous genetic and environmental factors. Insulin is the only treatment and preventative strategies do not currently exist. An obvious need exists to develop a safe regimen that suppresses the progression of the disease. Areas covered: A MEDLINE search (1966-June 2011) was conducted for English-language articles using the terms 'otelixizumab', 'anti-CD3 antibody' and 'prevention of type 1 diabetes mellitus'. Relevant literature on otelixizumab, an anti-CD3 monoclonal antibody, currently in Phase III clinical trials for prevention of T1DM is discussed. Expert opinion: Studies suggest that a monoclonal antibody directed against CD3 mitigates the deterioration in insulin production and decreases the rise in insulin requirement in recent onset T1DM for up to five years. The benefit was most pronounced in younger patients and in those with higher initial β-cell function. Adverse effects were significant but transient. Otelixizumab shows great promise but leaves room for improvement. Results of ongoing trials will help define its role in the prevention of T1DM.
Authors:
Shannon A Miller; Erin St Onge
Related Documents :
15855254 - Liver fat and insulin resistance are independently associated with the -514c>t polymorp...
15107844 - Pgc-1 promotes insulin resistance in liver through ppar-alpha-dependent induction of tr...
21329624 - Cost-effectiveness of insulin glargine versus nph insulin for the treatment of type 2 d...
1374854 - High serum alkaline phosphatase level of meningioma cell origin: case report and review...
1751204 - A simple and practical method for assessing the adequacy of hemodialysis.
7882824 - Relationship between dairy product consumption and incidence of iddm in childhood in it...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2011-9-14
Journal Detail:
Title:  Expert opinion on biological therapy     Volume:  -     ISSN:  1744-7682     ISO Abbreviation:  -     Publication Date:  2011 Sep 
Date Detail:
Created Date:  2011-9-14     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101125414     Medline TA:  Expert Opin Biol Ther     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Affiliation:
Florida Hospital East, Pharmacotherapy Faculty, Family Practice Residency, Family Health Center East, 7975 Lake Underhill Road, Suite 200, Orlando, FL 32822 , USA +1 407 303 6830 ; +1 407 303 6839 ; Shannon.miller@flhosp.org.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Formulation, in vitro, and in vivo evaluation of matrix-type transdermal patches containing olanzapi...
Next Document:  Quiescent stem cells in intestinal homeostasis and cancer.